CBD, one of the cannabinoids present in hemp, is much studied for its various possible actions on the human body. In this previous article, we mentioned its application on arthritis. A recently published study confirms its action on pain, anxiety, and depression.
The New Zealand CBD Study
Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) was amended, allowing doctors to prescribe CBD in New Zealand.
The purpose of the study was to measure the overall impact of CBD on quality of life, its tolerability and how dosage may affect outcomes in patients who were prescribed CBD oil for a variety of conditions in a single facility. It was published in the British Journal of General Practice Open. It can be viewed by clicking on this link.
400 patients surveyed on quality of life and CBD (pain, stress)
An audit was conducted on 400 patients who are treated at Cannabis Care in New Zealand between December 7, 2017, and December 7, 2018. These patients had recently been prescribed CBD oil for various conditions.
Study participants were interviewed before taking CBD and again after three weeks of CBD use. Follow-up was completed in 63.3% of them or 253 patients.
According to the returns from the study, after 3 weeks of use in the patients concerned, the patients returned an average increase in quality of life of 13.6 points on the EQ-VAS scale, which describes the overall quality of life and health felt.
Participants also saw an improvement in some symptoms: those with mental health problems experienced a significant improvement in their symptoms of depression and anxiety, as well as a reduction in pain and an increased ability to carry out their usual activities.
Patients with non-cancer pain also experienced significant improvements in pain, anxiety, and the ability to carry out usual activities. Those with cancer-related symptoms saw an improvement in their pain level, but to a lesser extent.
Interestingly, patients with neurological symptoms (e.g. Parkinson’s disease, epilepsy, and autism) did not see statistically significant improvements in any of the areas measured after CBD treatment.
Positive side effects included improvements in sleep and appetite.
No association was found between the dose of CBD and the benefit reported by the patient. This is consistent with what is explained in the article on the use of CBD and its dosage.
Conclusion of the study
There may be analgesic and anxiolytic benefits of CBD in patients with chronic non-cancer pain and mental health problems such as anxiety. CBD is well tolerated, making it safe for testing for chronic non-cancer pain, mental health, neurological, and cancer symptoms.